Isoptin Sr-e 240

Leaflet accompanying the packaging: patient information

Warning! Keep the leaflet! Information on the immediate packaging in a foreign language.

Isoptin SR-E 240 (Isoptine L.P. 240 mg), 240 mg, prolonged-release tablets
Verapamil hydrochloride
Isoptin SR-E 240 and Isoptine L.P. 240 mg are different trade names for the same medicine.

It is essential to carefully read the contents of the leaflet before taking the medicine, as it contains important information for the patient.

• The leaflet should be kept so that it can be re-read if necessary.
• In case of any doubts, the doctor or pharmacist should be consulted.
• This medicine has been prescribed to a specific person. It should not be given to others. The medicine may harm another person, even if the symptoms of their illness are the same.
• If the patient experiences any side effects, including any side effects not listed in the leaflet, they should inform their doctor or pharmacist. See section 4.

Table of contents of the leaflet:

• 1. What is Isoptin SR-E 240 and what is it used for
• 2. Important information before taking Isoptin SR-E 240
• 3. How to take Isoptin SR-E 240
• 4. Possible side effects
• 5. How to store Isoptin SR-E 240
• 6. Contents of the packaging and other information

1. What is Isoptin SR-E 240 and what is it used for

Isoptin SR-E 240 is available in the form of prolonged-release tablets containing 240 mg of the active substance - verapamil hydrochloride. Verapamil hydrochloride is a selective calcium antagonist acting directly on the heart muscle.
The action of the medicine is based on the inhibition of calcium ion passage through the cell membrane to the heart muscle cells and vascular smooth muscle cells.
The medicine has antihypertensive and antiarrhythmic effects.
The antihypertensive effect of the medicine is the result of reduced peripheral resistance without a significant increase in heart rate. In the case of normal arterial pressure, the medicine does not have a significant hypotensive effect.
The antiarrhythmic effect, especially in the case of supraventricular rhythm disorders, is based on the slowing of conduction in the atrioventricular node. As a result, there is a restoration of sinus rhythm and/or normalization of ventricular contractions, depending on the type of rhythm disorder. The medicine does not change the normal heart rate or only slightly reduces it.
Isoptin SR-E 240 is indicated for use in adults for the treatment of:

• hypertension
• coronary heart disease (conditions characterized by insufficient oxygen supply to the heart muscle), including:
• chronic stable angina pectoris
• unstable angina pectoris (with increasing pain, pain at rest)
• Prinzmetal's angina
• angina after myocardial infarction without heart failure, when beta-blockers are not indicated
• arrhythmias such as:
• paroxysmal supraventricular tachycardia, atrial fibrillation/flutter with rapid atrioventricular conduction (except for Wolff-Parkinson-White syndrome [WPW] or Lown-Ganong-Levine syndrome [LGL])

2. Important information before taking Isoptin SR-E 240

When not to take Isoptin SR-E 240

• if the patient is allergic to verapamil hydrochloride or any of the other ingredients of this medicine (listed in section 6)
• in cardiogenic shock
• in atrioventricular block II˚ or III˚ (except for patients with a functioning pacemaker)
• in sick sinus syndrome (except for patients with a functioning pacemaker)
• in heart failure with reduced ejection fraction below 35% and/or pulmonary capillary wedge pressure above 20 mmHg (if not secondary to supraventricular tachycardia responding to verapamil treatment)
• in atrial fibrillation/flutter with accessory conduction (e.g. Wolff-Parkinson-White syndrome [WPW], Lown-Ganong-Levine syndrome [LGL]). In these patients, there is a risk of ventricular tachyarrhythmia, including ventricular fibrillation
• if the patient is taking ivabradine

Warnings and precautions

Before starting treatment with Isoptin SR-E 240, the doctor should be consulted.
Particular caution should be exercised in patients:

• with acute myocardial infarction complicated by bradycardia, significant hypotension, or left ventricular dysfunction
• with heart block, atrioventricular block I˚, bradycardia, asystole
• taking antiarrhythmic drugs, beta-blockers
• taking digoxin
• with heart failure with ejection fraction above 35%
• with hypotension
• taking statins
• with neuromuscular transmission disorders [myasthenia gravis, Lambert-Eaton syndrome, late stages of Duchenne muscular dystrophy]
• with renal dysfunction
• with severe liver dysfunction

Isoptin SR-E 240 and other medicines

The doctor should be informed about all medicines currently taken by the patient or recently taken, including those planned to be taken.
Interactions with verapamil are possible with the following medicines:

• alpha-blockers (e.g. prazosin, terazosin)
• antiarrhythmic drugs (e.g. flecainide, quinidine)
• bronchodilators (e.g. theophylline)
• antiepileptic drugs (e.g. carbamazepine, phenytoin)
• antidepressants (e.g. imipramine)
• antidiabetic drugs (e.g. gliburyde)
• drugs for gout (e.g. colchicine)
• antibiotics (e.g. clarithromycin, erythromycin, rifampicin, telithromycin)
• anticancer drugs (e.g. doxorubicin)
• barbiturates (e.g. phenobarbital)
• benzodiazepines and other anxiolytic drugs (e.g. buspirone, midazolam)
• beta-blockers (e.g. metoprolol, propranolol)
• digitalis glycosides (e.g. digitoxin, digoxin)
• H2 receptor antagonists (e.g. cimetidine)
• immunomodulating and immunosuppressive drugs (e.g. cyclosporine, everolimus, sirolimus, tacrolimus)
• lipid-lowering drugs (e.g. atorvastatin, lovastatin, simvastatin)
• serotonin receptor agonists (e.g. almotriptan)
• drugs increasing uric acid excretion (e.g. sulfinpyrazone)
• dabigatran (anticoagulant) and direct oral anticoagulants
• ivabradine (used in the treatment of heart diseases), see "When not to take Isoptin SR-E 240"
• metformin (used in the treatment of diabetes). Verapamil may reduce the glucose-lowering effect of metformin.

Isoptin SR-E 240 with food and drink

Interactions with grapefruit juice and products containing St. John's wort extract are also possible.
Additional information on some interactions is provided below.
Antiviral drugs against human immunodeficiency virus (HIV)
Ritonavir may increase verapamil plasma concentrations, enhancing its effect. Caution should be exercised when these drugs are used together, and if necessary, the verapamil dose should be reduced.
Lithium
Increased sensitivity to lithium (neurotoxicity) has been reported during concomitant treatment with Isoptin SR-E 240 and lithium without changes or with increased lithium serum concentrations. However, the addition of Isoptin SR-E 240 also resulted in decreased lithium serum concentrations in patients chronically receiving oral fixed doses of lithium. Patients receiving both drugs should be closely monitored.
Muscle relaxants
The medicine may enhance the effect of muscle relaxants (curare-like and depolarizing drugs). It may be necessary to reduce the dose of Isoptin SR-E 240 and/or the dose of the muscle relaxant when these drugs are used together.
Acetylsalicylic acid
Increased risk of bleeding.
Ethanol
Increased ethanol plasma concentration.
HMG-CoA reductase inhibitors (statins)
When treating patients with Isoptin SR-E 240, HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin, or lovastatin) should be started at the lowest possible dose, which can then be gradually increased.
If the patient is already taking an HMG-CoA reductase inhibitor (e.g. simvastatin, atorvastatin, or lovastatin), consideration should be given to reducing the statin dose and then re-adjusting it based on serum cholesterol levels.
The likelihood of interaction with fluvastatin, pravastatin, or rosuvastatin is lower.
Hypotensive, diuretic, and vasodilatory drugs
Enhanced hypotensive effect.

Pregnancy and breastfeeding

If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor before taking this medicine.
There are no data on the use of the medicine in pregnant women, and therefore, the medicine should only be used during pregnancy if it is absolutely necessary.
The medicine passes into breast milk in a small percentage. It cannot be ruled out that there is a risk to newborns and infants. However, due to the possibility of severe side effects in breastfed infants, the medicine can be used during breastfeeding only if it is essential for the mother's health.

Driving and operating machinery

In some patients, Isoptin SR-E 240 may affect their ability to react to such an extent that it impairs their ability to drive vehicles, operate machinery, or work in hazardous conditions. This is especially true during the initial treatment period, when increasing the dose, when switching from another medicine, and when consuming alcohol. The medicine may increase ethanol plasma concentration and delay its elimination. Therefore, the effect of alcohol may be enhanced.

Isoptin SR-E 240 contains tartrazine (E 104)

Isoptin SR-E 240 contains tartrazine (E 104), which may cause allergic reactions in some patients.

Isoptin SR-E 240 contains sodium

Isoptin SR-E 240 contains 37.1 mg of sodium (the main component of common salt) per tablet.
This corresponds to 1.9% of the maximum recommended daily sodium intake for adults.

3. How to take Isoptin SR-E 240

This medicine should always be taken according to the doctor's recommendations. In case of doubts, the doctor or pharmacist should be consulted.
The dose of the medicine should be individualized based on the severity of the disease. Long-term clinical experience confirms that in all indications, the daily dose is usually between 240 mg and 360 mg. During long-term treatment, the daily dose should not exceed 480 mg, while in short-term treatment, a higher dose can be used. The duration of treatment is unlimited. After long-term treatment, the medicine should not be abruptly discontinued. A gradual dose reduction is recommended.
Oral administration. The tablet should be swallowed whole (not sucked or chewed), with a sufficient amount of liquid, preferably during or immediately after a meal.
Adults and adolescents over 50 kg of body weight
Hypertension: 120 mg to 480 mg per day in one or two divided doses.
Coronary heart disease, paroxysmal supraventricular tachycardia, atrial fibrillation, and atrial flutter: 120 mg to 480 mg per day in one or two divided doses.
If a dose of 120 mg is necessary, the Isoptin SR 120 mg prolonged-release tablets should be used.
In patients who may show a satisfactory response to small doses (e.g. patients with liver dysfunction or elderly patients), Isoptin 40 mg or Isoptin 80 mg tablets should be used.
Special populations
Children and adolescents
Isoptin SR-E 240 should not be used in children. In children, non-modified release medicines should be used.
Renal impairment
When using the medicine in patients with renal impairment, caution should be exercised, and the patient's condition should be closely monitored.
Hepatic impairment
In patients with liver dysfunction, the metabolism of the medicine is impaired to varying degrees, depending on the degree of liver dysfunction, which makes the medicine more potent and longer-acting. Therefore, particular caution should be exercised when determining the dose in patients with liver dysfunction, and small doses should be administered in the initial treatment period (see "Warnings and precautions").

Overdose of Isoptin SR-E 240

Symptoms
Hypotension, bradycardia, slowing of conduction up to high-degree atrioventricular block and sinus arrest, hyperglycemia, stupor, metabolic acidosis, acute respiratory failure. Overdose has led to death.
Treatment
In case of overdose, supportive treatment should be administered, individually tailored. In the treatment of intentional overdose of the medicine, beta-adrenergic stimulation and/or parenteral calcium (calcium chloride) have been effectively used. In case of clinically significant hypotension or high-degree atrioventricular block, vasopressor drugs or cardiac pacing should be used. In case of asystole, standard procedures, including beta-adrenergic stimulation (e.g. isoproterenol hydrochloride), other vasopressor drugs, or cardiopulmonary resuscitation, should be used.
If there is an overdose of verapamil hydrochloride in a prolonged-release form, due to slower absorption of the medicine, the patient should be hospitalized and monitored for up to 48 hours. Verapamil hydrochloride cannot be removed from the body by hemodialysis.

Missed dose of Isoptin SR-E 240

A double dose should not be taken to make up for a missed dose.

Discontinuation of Isoptin SR-E 240

After long-term treatment, the medicine should not be abruptly discontinued. A gradual dose reduction is recommended.

4. Possible side effects

Like all medicines, Isoptin SR-E 240 can cause side effects, although not everybody gets them.
The most common side effects were: headache, dizziness, gastrointestinal disorders: nausea, constipation, and abdominal pain, as well as bradycardia, tachycardia, palpitations, hypotension, flushing, peripheral edema, and fatigue.
Side effects are listed below by system organ class:
Common(in 1 to 10 patients out of 100):

• central dizziness, headache
• bradycardia
• flushing, hypotension
• constipation, nausea
• peripheral edema

Uncommon(in 1 to 10 patients out of 1000):

• palpitations, tachycardia
• abdominal pain
• fatigue

Rare(in 1 to 10 patients out of 10,000):

• paresthesia, muscle tremors
• drowsiness
• tinnitus
• vomiting
• excessive sweating

Side effects with unknownfrequency (frequency cannot be estimated from available data):

• hypersensitivity reactions
• extrapyramidal disorders, seizures
• hyperkalemia
• peripheral dizziness
• atrioventricular block (I˚, II˚, III˚), heart failure, sinus arrest, sinus bradycardia, asystole (cardiac arrest)
• bronchospasm, dyspnea
• abdominal discomfort, gingival hyperplasia, intestinal obstruction
• angioedema, Stevens-Johnson syndrome, erythema multiforme, alopecia, pruritus, urticaria, rash, erythematous rash
• arthralgia, muscle weakness, myalgia
• renal failure
• erectile dysfunction, galactorrhea, gynecomastia
• increased prolactin levels, increased liver enzyme activity

After the medicine was placed on the market, one case of paralysis (quadriparesis) was reported after concomitant use of verapamil and colchicine.
If any side effect worsens or any side effect not listed in the leaflet occurs, the doctor or pharmacist should be informed.

Reporting side effects

If side effects occur, including any side effects not listed in the leaflet, the doctor or pharmacist should be informed. Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Reporting side effects will help gather more information on the safety of the medicine.

5. How to store Isoptin SR-E 240

The medicine should be stored out of sight and reach of children.
The medicine should not be used after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
The medicine should not be stored above 25°C.
Medicines should not be disposed of via wastewater or household waste. The pharmacist should be asked how to dispose of unused medicines. This will help protect the environment.

6. Contents of the packaging and other information

What Isoptin SR-E 240 contains

The active substance of the medicine is verapamil hydrochloride 240 mg.
The excipients are: microcrystalline cellulose, sodium alginate, povidone, magnesium stearate, purified water, and the tablet coating: hypromellose, macrogol 400, macrogol 6000, talc, titanium dioxide (E 171), tartrazine (E 104), and indigo carmine (E 132), and Montana glyceride wax (Hoechst wax E).

What Isoptin SR-E 240 looks like and contents of the packaging

The tablet is light green, oblong.
Isoptin SR-E 240 is available in packs containing:
20 tablets (2 blisters of 10 tablets each)
40 tablets (4 blisters of 10 tablets each)
PVC/PVDC/Aluminum blisters in a cardboard box.
For more detailed information, the marketing authorization holder or parallel importer should be contacted.

Marketing authorization holder in France, the country of export:

Viatris Médical, 1 bis place de la Défense, Tour Trinity, F 92400 Courbevoie, France

Manufacturer:

Famar A.V.E. Anthoussa Plant, Anthoussa Avenue 7, Anthoussa Attiki, 15349, Greece
Mylan Hungary kft., Mylan utca 1, Komarom, 2900, Hungary

Parallel importer:

InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw

Repackaged by:

InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in France, the country of export:34009 328 674 1 7
34009 371 524 8 8

Parallel import authorization number: 351/24

Date of leaflet approval: 02.10.2024

[Information about the trademark]